When antidepressants are not working, finding treatment-resistant depression treatment and understanding your depression treatment options can feel overwhelming. You may wonder whether the medication failed, whether you failed, or whether there is anything left to try.
We want to be clear about one thing first. Depression that has not improved enough is not a personal failure. It is information. It tells us that your symptoms deserve a closer look. That includes the medication, its dose and duration, your diagnosis, your health history, and the support around you.
For many people, this is also where the language becomes confusing. “The medication did not work” can mean several different things. Understanding those differences can make your next conversation with a qualified mental health professional more useful and less overwhelming.
Not feeling better is not always treatment resistance
An antidepressant may not have helped for reasons that have nothing to do with whether depression is “severe enough” or whether you are out of options.
Sometimes, a medication trial was inadequate. The dose may not have been optimized. The medication may not have been taken long enough to judge its effect. Side effects may have made it impossible to continue. Practical barriers matter too. Cost, gaps in prescription access, or a demanding schedule can make regular dosing difficult.
Sometimes, a medication was not tolerated. A drug can be clinically reasonable and still be the wrong fit for your body. Sleep disruption, sexual side effects, emotional flattening, agitation, stomach symptoms, or other unwanted effects may lead someone to stop before a full trial is possible. That does not prove that every antidepressant approach will fail.
Then there is partial response. Perhaps you are getting out of bed more often, but the heaviness has not lifted. Perhaps concentration has improved, but pleasure and hope still feel far away. Partial response matters. It may point toward a medication adjustment, added support, psychotherapy, or a fuller reassessment instead of simply starting over.
Depression can also overlap with anxiety, trauma symptoms, chronic pain, sleep problems, substance use concerns, or medical conditions. Our discussion of anxiety and depression explores why symptoms can overlap and make it harder to see what needs attention first. Trauma symptoms can be another important part of the picture, especially for people living with PTSD.
Treatment-resistant depression treatment options when antidepressants are not working
Treatment-resistant depression, often shortened to TRD, is generally used when a person has not had adequate benefit from more than one appropriate antidepressant treatment. The details matter. A meaningful assessment considers whether treatments fit the diagnosis, were adequately dosed, were taken consistently, and had enough time to work. It also considers whether they could be tolerated.
There is no benefit to applying the label too quickly. But there is also no benefit to minimizing ongoing depression after several thoughtful attempts. Clinical guidance on treatment-resistant depression emphasizes revisiting diagnosis, medication history, co-occurring conditions, psychotherapy, and medical contributors before deciding what comes next (Voineskos et al., 2020). Earlier management recommendations similarly describe the value of a careful review before changing course (Keitner et al., 2012).
We encourage you to bring specifics to your appointment:
Every medication you have tried, including approximate dose and duration
What changed, if anything, in your mood, sleep, energy, focus, appetite, and daily life
Side effects that limited treatment
Other therapies you have tried, including psychotherapy
Alcohol, cannabis, or other substance use that could affect symptoms or medication response
Major stressors, trauma history, chronic pain, hormonal changes, and medical concerns
This is not busywork. It helps distinguish a medication that was never fully tested from a well-conducted trial that did not provide enough relief.
The next step is often a reassessment, not just another prescription
When depression persists, it can be tempting to view the next medication as a coin toss. We take a more deliberate approach. The question is not only, “What have you tried?” It is also, “What happened when you tried it?”
A prescriber may consider whether the original diagnosis still fits. They may look for bipolar-spectrum symptoms, sleep concerns, thyroid issues, or another condition affecting mood. They may also review whether psychotherapy has been available and useful. Research on augmentation and combination approaches reflects the range of next-step strategies clinicians may consider for early-stage TRD (Scott et al., 2023).
Some people need a medication change. Some need an added medication. Some need care that addresses trauma, relationships, pain, sleep, or the nervous system more directly. The right question is not, “Why am I still struggling?” A better question is, “What has my experience taught us about what should be evaluated next?”
Where IV ketamine therapy fits into the conversation
At Vitalitas Denver, we offer IV ketamine therapy in Denver for treatment-resistant depression. Ketamine for psychiatric use is off-label, meaning it is not FDA-approved specifically for depression. It is not automatically appropriate because an antidepressant has not helped. A history of nonresponse alone does not establish candidacy.
Instead, candidacy involves a careful medical and psychiatric review. We look at your symptoms, treatment history, current medications, medical conditions, safety considerations, and goals. If you are wondering what that assessment can involve, read our practical candidacy self-check.
IV ketamine has been studied as an adjunctive option for adults with treatment-resistant depression, including in a controlled intravenous ketamine trial (Fava et al., 2020). Researchers are also studying glutamate-related pathways in major depression. These pathways differ from those most often linked with traditional antidepressants, as described in research on glutamatergic treatments (McIntyre et al., 2024). You can learn more about glutamate signaling and why it is part of this broader clinical conversation.
Other depression care options may also be discussed with your prescribing clinician. These may include psychotherapy, medication changes or augmentation, transcranial magnetic stimulation, which is FDA-cleared, electroconvulsive therapy, or SPRAVATO® where clinically appropriate. These are not interchangeable choices. Each requires individualized evaluation.
Questions worth bringing to your next appointment
If you feel stuck, you do not need to arrive with the answer. Bring the questions.
Was each antidepressant trial adequate in dose and duration?
Did I have no response, partial response, or side effects that prevented a full trial?
Could another diagnosis, medical issue, medication, or substance be affecting my symptoms?
What role could psychotherapy or lifestyle support play alongside medical care?
What treatment options make sense for my history, and what are their risks and practical requirements?
Would an evaluation for treatment-resistant depression be appropriate?
We also believe that medical supervision matters. Ketamine is a medication that calls for thoughtful screening, monitoring, and follow-up. It is not a shortcut or a product to manage alone. Our perspective on medical supervision explains why this distinction is important.
You deserve care that takes your history seriously
Living with unresolved depression can narrow your world. It can make ordinary tasks feel impossible. It can also make it harder to imagine a different future. We meet many people who have spent years trying to explain that their medication helped a little, but not enough.
If that is where you are, we invite you to approach the next step with curiosity rather than self-blame. A careful review can clarify whether you are dealing with an incomplete medication trial, intolerance, partial response, treatment-resistant depression, or several factors at once. Our role is to help you have an informed, medically supervised conversation about IV ketamine therapy and whether it may be appropriate within your broader care plan.
If you are in immediate danger, having thoughts of suicide, or feel unable to stay safe, call or text 988 for the 988 Suicide and Crisis Lifeline (988 Suicide and Crisis Lifeline, n.d.), call 911, or go to the nearest emergency department.
Works Cited
Voineskos D, et al. Management of Treatment-Resistant Depression: Challenges and Strategies. https://pubmed.ncbi.nlm.nih.gov/32021216/
Keitner GI, et al. Management of treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/22370501/
Scott F, et al. Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/35861202/
Fava M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression. https://pubmed.ncbi.nlm.nih.gov/30283029/
McIntyre RS, et al. Glutamatergic Modulators for Major Depression from Theory to Clinical Use. https://pubmed.ncbi.nlm.nih.gov/39150594/
988 Suicide and Crisis Lifeline. https://988lifeline.org/
Disclaimer
This article is for educational purposes only and is not a substitute for individualized evaluation, diagnosis, or treatment from a qualified healthcare professional.
